FDA approves Bristol-Myers Squibb’s Evotaz™ (atazanavir and cobicistat)
Bristol-Myers Squibb announced the FDA has approved Evotaz (atazanavir 300 mg and cobicistat 150 mg) tablets in combination with other antiretroviral agents for treatment of HIV-1 infection in adults. Evotaz is marketed by Gilead Sciences. January 29, 2015